Literature DB >> 14656992

Hair growth induction by the Tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression.

Benjamin Sredni1, Rivka Gal, Ian J Cohen, Jean-Eudes Dazard, David Givol, Uzi Gafter, Benny Motro, Siona Eliyahu, Michael Albeck, Harry M Lander, Yona Kalechman.   

Abstract

The synthetic immunomodulator AS101[ammonium trichloro(dioxoethylene-o,o')tellurate] was previously found to protect cancer patients from chemotherapy-induced bone marrow toxicity and alopecia. Here we show that AS101 induces hair growth in nude and normal mice. AS101 possesses the dual ability to both induce anagen and retard spontaneous catagen in the C57BL/6 mouse model. Anagen induced by AS101 is mediated by keratinocyte growth factor (KGF), as it is abrogated both in nude mice co-treated with AS101 plus neutralizing anti KGF antibodies and in AS101-treated transgenic mice expressing a dominant-negative KGF receptor transgene in basal keratinocytes. AS101 up-regulates KGF expression by activating the ras signaling pathway in cultured fibroblasts. AS101-induced delayed catagen is associated with inhibition of terminal differentiation marker expression both in nude and C57BL/6 mice epidermal follicular keratinocytes and in cultures of primary mouse follicular keratinocytes induced to differentiate. This activity is associated with relatively sustained elevation of p21waf. Delayed expression of terminal differentiation markers was not induced by AS101 in follicular keratinocytes from p21waf knockout mice. Because similar results were obtained with cultures of primary human keratinocytes and fibroblasts, preliminary case report studies revealed substantial hair growth when AS101 was topically applied on three adolescents who had remained alopeciac 1-2 years after chemotherapy. The results emphasize the unique mode of action of AS101 and highlight its potential clinical use for treating certain types of alopecia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656992     DOI: 10.1096/fj.03-0552fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  6 in total

1.  Multifunctional activity of a small tellurium redox immunomodulator compound, AS101, on dextran sodium sulfate-induced murine colitis.

Authors:  Gilad Halpert; Tom Eitan; Elena Voronov; Ron N Apte; Lea Rath-Wolfson; Michael Albeck; Yona Kalechman; Benjamin Sredni
Journal:  J Biol Chem       Date:  2014-04-24       Impact factor: 5.157

2.  The anti-inflammatory effects of the tellurium redox modulating compound, AS101, are associated with regulation of NFkappaB signaling pathway and nitric oxide induction in macrophages.

Authors:  Miri Brodsky; Gilad Halpert; Michael Albeck; Benjamin Sredni
Journal:  J Inflamm (Lond)       Date:  2010-01-20       Impact factor: 4.981

3.  Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNS.

Authors:  Jun-Ho Lee; Meital Halperin-Sheinfeld; Dolgar Baatar; Mohamed R Mughal; Hyun-Jin Tae; Jie-Wan Kim; Arnell Carter; Ana Lustig; Omri Snir; Gad Lavie; Eitan Okun; Mark P Mattson; Benjamin Sredni; Dennis D Taub
Journal:  Neuromolecular Med       Date:  2013-11-23       Impact factor: 3.843

4.  Beneficial effects of Astragaloside IV for hair loss via inhibition of Fas/Fas L-mediated apoptotic signaling.

Authors:  Mi Hye Kim; Sung-Hoon Kim; Woong Mo Yang
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

Review 5.  Signaling mechanisms and disrupted cytoskeleton in the diphenyl ditelluride neurotoxicity.

Authors:  Regina Pessoa-Pureur; Luana Heimfarth; João B Rocha
Journal:  Oxid Med Cell Longev       Date:  2014-06-22       Impact factor: 6.543

6.  The small tellurium-based compound SAS suppresses inflammation in human retinal pigment epithelium.

Authors:  Rima Dardik; Tami Livnat; Gilad Halpert; Shayma Jawad; Yael Nisgav; Shirley Azar-Avivi; Baoying Liu; Robert B Nussenblatt; Dov Weinberger; Benjamin Sredni
Journal:  Mol Vis       Date:  2016-05-28       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.